Michael J Allingham
Overview
Explore the profile of Michael J Allingham including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
754
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Taha A, Shen L, Diaz A, Chahal N, Saroya J, Sun M, et al.
Ophthalmol Sci
. 2024 Nov;
5(1):100620.
PMID: 39584185
Purpose: To investigate the association between rim area focal hyperautofluorescence (RAFH) signals and geographic atrophy (GA) growth rates, as well as the impact of oral metformin on the longitudinal change...
2.
Dow E, Jeong H, Katz E, Toth C, Wang D, Lee T, et al.
JAMA Ophthalmol
. 2023 Oct;
141(11):1052-1061.
PMID: 37856139
Importance: The identification of patients at risk of progressing from intermediate age-related macular degeneration (iAMD) to geographic atrophy (GA) is essential for clinical trials aimed at preventing disease progression. DeepGAze...
3.
Soifer M, Azar N, Blanco R, Mousa H, Ghalibafan S, Tovar A, et al.
Ocul Surf
. 2022 Dec;
27:77-79.
PMID: 36464234
No abstract available.
4.
Allingham M, Mettu P, Cousins S
Ophthalmol Sci
. 2022 Oct;
2(1):100095.
PMID: 36246187
Purpose: To assess safety, tolerability, and feasibility of subcutaneous administration of the mitochondrial-targeted drug elamipretide in patients with intermediate age-related macular degeneration (AMD) and high-risk drusen (HRD) and to perform...
5.
Mettu P, Allingham M, Cousins S
Ophthalmol Sci
. 2022 Oct;
2(1):100086.
PMID: 36246181
Purpose: Assess the safety, tolerability, and feasibility of subcutaneous administration of the mitochondrial-targeted drug elamipretide in patients with dry age-related macular degeneration (AMD) and noncentral geographic atrophy (NCGA) and to...
6.
Allingham M, Loksztejn A, Cousins S, Mettu P
Adv Exp Med Biol
. 2021 Apr;
1256:143-189.
PMID: 33848001
Increasing evidence over the past two decades points to a pivotal role for immune mechanisms in age-related macular degeneration (AMD) pathobiology. In this chapter, we will explore immunological aspects of...
7.
Mettu P, Allingham M, Cousins S
Prog Retin Eye Res
. 2020 Oct;
82:100906.
PMID: 33022379
Intravitreal anti-vascular endothelial growth factor (VEGF) drugs have revolutionized the treatment of neovascular age-related macular degeneration (NVAMD). However, many patients suffer from incomplete response to anti-VEGF therapy (IRT), which is...
8.
Rasti R, Allingham M, Mettu P, Kavusi S, Govind K, Cousins S, et al.
Biomed Opt Express
. 2020 Mar;
11(2):1139-1152.
PMID: 32133239
Anti-vascular endothelial growth factor (VEGF) agents are widely regarded as the first line of therapy for diabetic macular edema (DME) but are not universally effective. An automatic method that can...
9.
Aldosterone as a mediator of severity in retinal vascular disease: Evidence and potential mechanisms
Allingham M, Mettu P, Cousins S
Exp Eye Res
. 2019 Sep;
188:107788.
PMID: 31479654
Diabetic retinopathy (DR) and retinal vein occlusion (RVO) are the two most common retinal vascular diseases and are major causes of vision loss and blindness worldwide. Recent and ongoing development...
10.
Wilkinson-Berka J, Suphapimol V, Jerome J, Deliyanti D, Allingham M
Exp Eye Res
. 2019 Aug;
187:107766.
PMID: 31425690
Angiotensin II and aldosterone are the main effectors of the renin-angiotensin aldosterone system (RAAS) and have a central role in hypertension as well as cardiovascular and renal disease. The localization...